Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen

30-Dec-2010 - Sweden

Swedish Orphan Biovitrum  announced that it has returned full development rights to Symphogen, co-developer of  Sym001, for ITP (Immune Thrombocytopenic Purpura) treatment and for HDN (Hemolytic Disease in Newborn) prophylaxis, for strategic reasons.

Sym001 is currently in clinical phase II for treatment of ITP and in ADP (anti-D Prophylaxis) to prevent HDN. The Sym001 program is based on Symphogen's recombinant polyclonal technology and has been jointly developed since 2006, from early preclinical to its current clinical phase. Swedish Orphan Biovitrum (Sobi) has now decided to opt out of the program to be able to focus fully on its late-stage development pipeline.

"We have appreciated the collaboration with Symphogen on this novel program which may offer patients significant value in the future.  With a maturing pipeline we have, however, been forced to prioritize the delivery of our late stage development portfolio", said Peter Edman, CSO of Sobi.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...